Zoledronic acid: A review of its use in the management of bone metastases and hypercalcaemia of malignancy

Drugs

Volumn 63, Issue 4, 2003, Pages 417-437

  Wellington, Keri ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINOGLYCOSIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; HYDROXYPROLINE; IBANDRONIC ACID; LOOP DIURETIC AGENT; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; PYRIDINOLINE; THALIDOMIDE; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BREAST CANCER; BRONCHOSPASM; CALCIUM BLOOD LEVEL; CANCER RECURRENCE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOKALEMIA; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEG EDEMA; LUNG NON SMALL CELL CANCER; MINERALIZATION; MORBIDITY; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PAIN ASSESSMENT; PROSTATE CANCER; QUALITY OF LIFE; RELAPSE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TUMOR GROWTH; VERTIGO; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; CLINICAL TRIALS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERCALCEMIA; IMIDAZOLES; KIDNEY;

EID: 0037287351     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363040-00009     Document Type: Review

References (51)

1. Pelger RCM, Soerdjbalie-Maikoe V, Hamdy NAT. Strategies for management of prostate cancer-related bone pain. Drugs Aging 2001; 18 (12): 899-911
2. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998 Mar; 16: 1218-25
3. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000 Mar; 18 (6): 1378-91
4. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997 Jan; 69 (1-2): 1-18
5. Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 2002 Jul; 10 (5): 399-407
6. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002 Sep 1; 20 (17): 3719-36
7. Lamy O, Burckhardt P. Hypercalcemia of malignancy: diagnosis and treatment options. Am J Cancer 2002; 1 (4): 277-92
8. Fulfaro F, Casuccio A, Ticozzi C, et al. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998 Dec; 78: 157-69
9. Coukell AJ, Markham A. Pamidronate: a review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 1998 Feb; 12: 149-68
10. Cheer SM, Noble S. Zoledronic acid. Drugs 2001; 61 (6): 799-805; discussion 806
11. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002 Feb 28; 346 (9): 653-61
12. Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone 2001 May; 28 (5): 461-4
13. Fromigué O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002 Jun; 25 (6): 539-46
14. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001 Feb; 296 (2): 235-42
15. Coxon FP, Helfrich MH, Van't Hof RJ, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000 Aug; 15 (8): 1467-76
16. Evans CE, Braidman IP. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 1994; 26: 95-107
17. Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000 Nov 1; 60 (21): 6001-7
18. Pataki A, Müller K, Green JR, et al. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997; 249: 458-68
19. Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001; 91 (1): 144-54
20. Berenson JR, Vescio RA, Rosen LS, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001 Mar: 7 (3): 478-85
21. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study. Cancer 2001 Apr 1; 91 (7): 1191-200
22. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-51
23. Body JJ, Lortholary A, Romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999; 14 (9): 1557-61
24. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998 Feb; 12 (2): 220-9
25. Derenne S, Amiot M, Barillé S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999 Dec; 14 (12): 2048-56
26. Gordon S, Helfrich MH, Sati HIA, et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002 Nov; 119 (2): 475-83
27. Witters L, Javeed M, Crispino J, et al. Inhibition of growth of human breast cancer cell lines with the combination of zoledronic acid and a COX-2 inhibitor. Eur J Cancer 2001 Oct; 37 Suppl. 6: 78
28. Fromigué O, Lagneaux L, Body J-J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000 Nov; 15 (11): 2211-21
29. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001 Apr 20; 84 (8): 1126-34
30. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002 May 6; 86 (9): 1479-86
31. Corey E, Brown LG, Quinn JE, et al. Effects of zoledronic acid on prostate cancer in vitro and in vivo. 92nd Annu Meet Am Assoc Cancer Res 2001 Mar; 42: 214 (plus poster)
32. Green JR, Seltenmeyer Y, Jaeggi KA, et al. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997; 80: 225-30
33. Berenson J, Ravera C, Ma P, et al. Population pharmacokinetics (PK) of Zometa [abstract no. 814]. Proceedings of the 36th Annu Meet American Society of Clinical Oncology; 2000 May 20-23; New Orleans (LO), LA9: 209a
34. Novartis Pharmaceuticals Corporation. Zometa (zoledronic acid for injection) prescribing information [online]. Available from URL: http://www.zometa.com [Accessed 2002 Nov 20]
35. Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001 Sep-2001 31; 7 (5): 377-87
36. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Zoledronic Acid Prostate Cancer Study Group. J Natl Cancer Inst 2002 Oct 2; 94 (19): 1458-68
37. Rosen L, Gordon D, Tchekmedyian S, et al. Zometa significantly increased the median time to first skeletal related event (SRE) in patients with osteolytic bone metastases from non-small cell lung cancer (NSCLC) and other solid tumours (OST). Lung Cancer 2001; 34 Suppl. 1: S67
38. Rosen L, Gordon DH, Dugan Jr W, et al. Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion [abtract no. 629]. Presented at the 27th European Society for Medical Oncology Congress, Oct 18-22 2002, Nice.
39. Coleman RE, Rosen LS, Gordon D, et al. Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis [abstract no. 355]. Presented at the 25th San Antonio Breast Cancer Symposium 2002. Dec 11-14.
40. Rosen L, Gordon D, Tchekmedyian S, et al. Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumours [abstract no. 1179 presented at the 38th Annu Meet American Society of Clinical Oncology, May 18-21, 2002, Orlando, [online]. Available from URL: http://www. asco.org [Accessed 2002 Sep 26]
41. Weinfurt KP, Li Y, Castel LD, et al. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer [abstract no. 662]. Presented at the 27th ESMO Congress, 2002 Oct 18-22 2002; Nice.
42. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19 (2): 558-67
43. Novartis Pharmaceuticals Corporation. The Zometa international site: European summary of product characteristics [online]. Available from URL: http://www.zometa.com/ eu_spc.html [Accessed 2002 Nov 20]
44. Callander NS, Roodman GD. Myeloma bone disease. Semin Hematol 2001; 38 (3): 276-85
45. Ripamonti C, Fulfaro F. Pathogenesis and pharmacological treatment of bone pain in skeletal metastases. Q J Nucl Med 2001; 45 (1): 65-77
46. Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 2002 Jun; 29 (3 Suppl. 11): 134-44
47. Smith MR, Camps J, Shasha D, et al. Randomized, placebo-controlled trial of zoledronic acid to prevent bone loss during initial androgen deprivation therapy for stage M0 prostate cancer [abstract]. Presented at the Third North American Symposium on Skeletal Complications of Malignancy, 2002 Apr 25-27, Bethesda (MD).
48. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane Review). In: The Cochrane Library. Oxford: Update Software 2002; (Issue 3)
49. Davidson TG. Conventional treatment of hypercalcemia of malignancy. Am J Health Syst Pharm 2001 Nov 15; 58 Suppl. 3: S8-15
50. Hotte SJ, Hirte HW, Rabbani SA, et al. Hypercalcemia of malignancy: pathophysiology diagnosis and treatment. Am J Cancer 2002; 1 (3): 179-87
51. Watters J, Gerrard G, Dodwell D. The management of malignant hypercalcaemia. Drugs 1996 Dec; 52 (6): 837-48